Is Bristol-Myers Squibb Company (NYSE:BMY) A Safe Bet For Investors?


Bristol-Myers Squibb Company (NYSE:BMY) closed its last session at $62.47. The stock traded within a range of $61.80 and $62.52. The company operates in the Healthcare sector with a market capitalization of 102.39 Million. Trading volume for Bristol-Myers Squibb Company was 6.59 Million in its previous trading session. Currently, Bristol-Myers Squibb Company (NYSE:BMY) has an average volume of 5.37 Million.

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma.

Analyst Views

Bristol-Myers Squibb Company (NYSE:BMY) received a Buy rating from 2 analysts. 0 analysts gave its stock an Outperform rating. 3 analysts say it’s a Hold while 0 analysts provided their expert opinion as Sell.

Bristol-Myers Squibb Company (NYSE:BMY) touched its 1-Year High price of $66.10 on 10/13/17 and its 1-Year Low price of $46.01 on 01/26/17.

EPS & Financials

Bristol-Myers Squibb Company (NYSE:BMY) reported its EPS in the last quarter as $0.75/Share lagging the analyst estimate of $0.77/Share by a difference of $-0.02. This showed a surprise of -2.6% in the last quarter earnings.

For the current quarter, 19 analysts are projecting a mean EPS of $0.67/share. According to their observations and findings, the stock could provide a high EPS of $0.73/share and a low EPS of $0.63/share.

Analysts believe that the company has the potential to earn average revenue of $5.32 Billion for the current quarter. According to their predictions high & low revenue estimates are 5.45 Billion and 5.21 Billion respectively.

Technical Analysis

By taking a look at the stock’s current statistics it can gauged that the stock candle is BULLISH with LOW volatility. Bristol-Myers Squibb Company (NYSE:BMY) has a 20-Day average volume of 5.44 Million. According to today’s trading volume Bristol-Myers Squibb Company is BELOW its 20-Day Avg. volume with the stock showing BELOW Abnormal volume in the past 150 days.

Moving average convergence divergence (MACD) shows that the stock is on a PRICE RELATIVITY trend. The trend for the past 10-days shows that the company was in BULLISH territory while an analysis of the last 40-Day trend shows a BULLISH signal. The 100-Day trend also shows a BULLISH trend as well.

The company currently has an insider ownership of 0.1 Percent and Institutional ownership of 71.3 Percent. The return on assets stands at 12.6%, Return on Equity currently is 28.2% and the Return on Investment value is 19.8%.

Bristol-Myers Squibb Company (NYSE:BMY) gross margin percentage stands at 72.6% while its operating margin for the past trailing twelve month is 27.3 percent and its overall profit margin (ttm) is 20.6 Percent. The stock is currently moving above its 20-Day Simple Moving Average of 1% with a 50-Day Simple Moving Average of 1.01 percent. As of today, the company has a SMA200 (200-day simple moving average) of 6.78 Percent. The Stock has YTD (year to date) performance of 1.94 percent.

The TTM operating margin for the company stands at 27.3%. The return on invested capital is at 19.8%, which is good, compared to its peers. The Free Cash Flow or FCF margin is 62.13.

The company’s stock is currently moving with a +ve distance from the 200 day SMA of approximately 6.78%, and has a solid year to date (YTD) performance of 1.94% which means that the stock is constantly adding to its value from the previous fiscal year end price.